Cambridge-based 4basebio has received Good Manufacturing Practice certification from the UK’s Medicines and Healthcare products Regulatory Agency, enabling the company to supply GMP-grade synthetic DNA for clinical applications in cell and gene therapy development.
The Cystic Fibrosis Foundation has committed up to US$2.3 million (about £1.7 million) in equity investment to Owlstone Medical for the development of a breath test to detect Pseudomonas aeruginosa (PA) infections in people with cystic fibrosis (CF). The Cambridge-based company announced the investment on March 25, 2025, marking a significant step forward in respiratory […]
Innovative assay requires minimal blood sample while providing high accuracy
A state-of-the-art pilot line environment established by VTT Technical Research Centre of Finland aims to bridge the critical gap between medical technology research and market-ready products, potentially reducing development timelines for non-invasive diagnostic and monitoring devices.
BioMed X Institute has announced a groundbreaking partnership with the Government of Barbados to launch BioMed X Barbados, a new research initiative tackling healthcare disparities in cardiometabolic disease treatment. The collaboration, supported by the European Commission’s PharmaNext programme, aims to address the underrepresentation of people of African descent in clinical research through advanced molecular characterisation […]
The revolutionary UV-150 photochemical reactor, employed alongside Vapourtec’s R-Series flow chemistry system, has enabled significant advancements in peptide modification techniques with potential to reshape pharmaceutical manufacturing.
Global healthcare company Sanofi has successfully priced a €1.5 billion bond issue, structured across two tranches with different maturity profiles and interest rate mechanisms. The financing move, announced on 5 March 2025, represents a significant capital raising exercise that strengthens the company’s financial position.
FORESIGHT consortium receives €9 million grant to accelerate drug development through advanced imaging technologies, addressing challenges in treating rising disease burdens across multiple therapeutic areas.
The Cambridge-based biotech company Shift Bioscience has announced the establishment of new facilities in Toronto, Canada, marking a strategic expansion of their AI capabilities in the development of virtual cell technology. The move follows their recent $16M seed funding round and positions the company to tap into North America’s rich pool of artificial intelligence talent.
Artificial Inc has successfully demonstrated the integration of NVIDIA’s BioNeMo generative AI platform with its laboratory orchestration system, showcasing capabilities for self-driving virtual screening in drug discovery applications. The proof-of-concept represents a significant technical advancement in applying AI technologies to pharmaceutical research workflows.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
